A phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (São Gonçalo do Amaranto, RN)

Valdemir Oliveira Da Silva, Gulnara P. Borja-Cabrera, Nubia N. Correia Pontes, Edilma Paraguai De Souza, Kleber G. Luz, Marcos Palatnik, Clarisa B. Palatnik De Sousa

Producción científica: Contribución a una revistaArtículorevisión exhaustiva

106 Citas (Scopus)

Resumen

Protection against canine kala-azar was investigated in naturally exposed dogs of an endemic area, vaccinated with the fucose mannose ligand (FML)-vaccine of Leishmania donovani. A total of 97% of vaccinees were seropositive to FML and 100% showed intradermal reaction to L. donovani lysate, 7 months after vaccination. The absorbency values and size of intradermal reaction were both significantly higher in vaccinees than in controls (ANOVA, P < 0.0001). After 2 years, 92% (χ2 = 6.996; P < 0.0025) protection was achieved: only 8% of vaccinees showed mild signs of kala-azar with no deaths while 33% of controls developed clinical or fatal disease. The FML-vaccine induced a significant, long-lasting and strong protective effect against canine kala-azar in the field.

Idioma originalInglés
Páginas (desde-hasta)1082-1092
Número de páginas11
PublicaciónVaccine
Volumen19
N.º9-10
DOI
EstadoPublicada - 8 dic. 2000
Publicado de forma externa

Huella

Profundice en los temas de investigación de 'A phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (São Gonçalo do Amaranto, RN)'. En conjunto forman una huella única.

Citar esto